Abstract
Bothersome vasomotor symptoms (ie, hot flashes or flushes and night sweats) are common after breast cancer, sometimes aggravated by chemotherapy-induced premature menopause or adjuvant endocrine treatments. Consequently, there is a long history of clinical trials testing a variety of centrally acting agents, including selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, and others,1,2 to manage vasomotor symptoms when menopausal oestrogen therapy (transdermal or oral oestrogens) is contraindicated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
